Drugs / polyethylene glycol
polyethylene glycol
also known as
PEG · Moviprep · BAY81-8430 · Golytely · Lovol-esse · Macrogol 4000 · MiraLAX · Movicol(PEG) · +12 more
Trials 46
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02359825 | Sep 2019 → May 2026 | peripheral nerve lesion | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT04730245 | Jun 2018 → Mar 2020 | Parkinson disease | Torre Médica Santé | Completed | No outcome recorded |
| Phase 1 | NCT02254629 | Jul 2014 → Aug 2015 | irritable bowel syndrome | Shandong University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00722410 | Sep 2008 → Sep 2010 | Klebsiella pneumonia | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07201311 | Jun 2026 → Jun 2028 expected | poisoning | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT04458129 | Sep 2020 → Apr 2022 | cystic fibrosis | University Hospital, Bordeaux | Terminated | No outcome recorded |
| Phase 2 | NCT02979223 | Nov 2016 → Jun 2017 | — | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2 | NCT01044394 | Jan 2010 → Jun 2011 | — | Boston Medical Center | Withdrawn | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05726097 | Feb → Oct 2023 | colorectal cancer, inflammatory bowel disease, polyp of colon | Region Skane | Completed | No outcome recorded |
| Phase 3 | NCT05076799 | Sep 2021 → Nov 2022 | — | Sichuan University | Completed | No outcome recorded |
| Phase 3 | NCT03315949 | May 2017 → Feb 2018 | — | Incheon St.Mary's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02731963 | Sep 2014 → Feb 2015 | anastomosing haemangioma | Mexican Social Security Institute | Completed | No outcome recorded |
| Phase 414 trials · 3 met primary · 2 missed | ||||||
| Phase 4 | NCT06748638 | Sep 2024 → Oct 2025 overdue | — | Haifeng Lan | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06666556 | Jul 2024 → Jul 2025 overdue | colorectal cancer | Hospital Civil de Guadalajara | Recruiting | No outcome recorded |
| Phase 4 | NCT05054036 | Jan 2022 → Jul 2024 | — | Yale University | Completed | Met primary |
| Phase 4 | NCT04436601 | Mar 2020 → Dec 2023 | hepatic encephalopathy | Aga Khan University | Unknown | No outcome recorded |
| Phase 4 | NCT04138004 | Dec 2019 → Jun 2021 | — | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
| Phase 4 | NCT03830489 | Feb → Oct 2019 | — | Hospital Universitario de Canarias | Completed | Missed primary |
| Phase 4 | NCT03738904 | Oct 2018 → Aug 2022 | anus disorder | Cedars-Sinai Medical Center | Completed | Met primary |
| Phase 4 | NCT03356015 | Dec 2017 → Jan 2018 | adenoma | Changhai Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02652637 | Mar 2016 → Sep 2018 | — | Helsinki University Central Hospital | Unknown | Missed primary |
| Phase 4 | NCT02119000 | Aug 2015 → Jan 2020 | — | McGill University Health Centre/Research Institute of the McGill University Health Centre | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02396017 | Mar → May 2015 | — | Centro Hospitalar Lisboa Ocidental | Unknown | Met primary |
| Phase 4 | NCT02070341 | Feb → Jul 2014 | — | Queen's University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01853709 | May → Dec 2013 | — | Corporacion Parc Tauli | Unknown | No outcome recorded |
| Phase 4 | NCT01622972 | Sep 2011 → Feb 2014 | constipation disorder, irritable bowel syndrome | University of Nottingham | Completed | No outcome recorded |
| Phase not applicable20 trials · 3 met primary | ||||||
| — | NCT07328880 | Apr 2025 → Apr 2026 overdue | — | Tanta University | Recruiting | No outcome recorded |
| — | NCT04199026 | Feb 2025 → Dec 2028 expected | sarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| — | NCT06728839 | Dec 2024 → Aug 2025 overdue | — | Changhai Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06994585 | Mar 2024 | — | Fu Jen Catholic University Hospital | Completed | No outcome recorded |
| — | NCT06364111 | Jan 2024 → Jun 2025 | constipation disorder | Beijing Tsinghua Chang Gung Hospital | Unknown | No outcome recorded |
| — | NCT07557173 | Jan 2024 → Jun 2026 overdue | — | Ospedale San Pio | Recruiting | No outcome recorded |
| — | NCT05291325 | May 2022 → Aug 2023 | — | Changhai Hospital | Completed | Met primary |
| — | NCT04434625 | Jun 2020 → Feb 2021 | — | Air Force Military Medical University, China | Completed | Met primary |
| — | NCT04033250 | Sep 2019 → Sep 2020 | — | Rambam Health Care Campus | Unknown | No outcome recorded |
| — | NCT03765216 | Jan → Feb 2019 | — | Shandong University | Unknown | No outcome recorded |
| — | NCT03704571 | Nov 2018 → Jul 2019 | — | Shandong University | Completed | No outcome recorded |
| — | NCT03495804 | Nov 2017 → Sep 2018 | chronic thromboembolic pulmonary hypertension | Shandong University | Unknown | No outcome recorded |
| — | NCT03248726 | Jul 2017 → Sep 2019 | — | Taipei Medical University WanFang Hospital | Completed | No outcome recorded |
| — | NCT03142854 | May → Jul 2017 | — | Shandong University | Completed | No outcome recorded |
| — | NCT03109951 | Mar 2017 → Dec 2019 | type 2 diabetes mellitus | Catholic Kwandong University | Completed | No outcome recorded |
| — | NCT02657564 | Jan 2016 → Jun 2017 | acute kidney injury | Evergreen General Hospital, Taiwan | Completed | No outcome recorded |
| — | NCT01929668 | Aug 2013 → Dec 2014 | ulcerative colitis | Kyungpook National University Hospital | Completed | No outcome recorded |
| — | NCT01561248 | May → Jun 2011 | escherichia coli infection, hemolytic-uremic syndrome, infectious colitis, intestinal infectious disease | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| — | NCT01610856 | Mar → Jun 2010 | — | University of Calgary | Completed | Met primary |
| — | NCT00288496 | Apr 1998 → Feb 2004 | — | Ikazia Hospital, Rotterdam | Completed | No outcome recorded |
| Comparator or background therapy64 trials | ||||||
| Phase 0 | NCT05542810 Background | Jan → Dec 2023 | — | GanHuoye | Unknown | No outcome recorded |
| Phase 0 | NCT05277090 Background | Mar 2022 | — | Yanqing Li | Unknown | No outcome recorded |
| Phase 0 | NCT03042091 Comparator | Sep 2016 → Oct 2020 | colorectal neoplasm, diverticulitis, inflammatory bowel disease | Thomas Jefferson University | Unknown | No outcome recorded |
| Phase 1 | NCT01243736 Comparator | Apr 2010 → Nov 2013 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01928862 Comparator | Jun 2014 → Feb 2017 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03328507 Comparator | Nov 2017 → Nov 2019 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 2/3 | NCT05341180 Comparator | May 2022 → Jul 2023 | constipation disorder | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 3 | NCT07668778 Background | Aug 2026 → Aug 2027 expected | cirrhosis of liver | Hospital do Divino Espírito Santo de Ponta Delgada | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07277907 Comparator | Nov 2025 → Oct 2027 expected | intestinal dysmotility syndrome | Third Military Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT02705378 Comparator | May 2017 → Apr 2019 | constipation disorder | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT01840553 Comparator | May 2013 → Mar 2014 | — | Laboratoires Mayoly Spindler | Completed | Met primary |
| Phase 3 | NCT01778192 Comparator | Jul → Nov 2012 | colon adenoma, colorectal cancer | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01568814 Comparator | Jan → Mar 2012 | — | Inje University | Completed | No outcome recorded |
| Phase 3 | NCT01415687 Comparator | May → Dec 2011 | — | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT01267981 Comparator | Sep 2010 → Jan 2016 | — | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT01229800 Comparator | Aug → Oct 2010 | — | Inje University | Completed | No outcome recorded |
| Phase 3 | NCT01065857 Comparator | Jan → Jun 2010 | — | Laboratorios Casen-Fleet S.L.U. | Completed | No outcome recorded |
| Phase 3 | NCT00687830 Comparator | Feb 2008 → Jul 2009 | colorectal cancer | Cleveland Clinic Florida | Completed | No outcome recorded |
| Phase 4 | NCT05083572 Background | Mar 2021 → Nov 2022 | immune dysregulation, neurodevelopmental defects, and colitis | Changi General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04281667 Background | Mar 2020 → Nov 2022 overdue | necrotizing soft tissue infection, rectum adenocarcinoma | Helsinki University Central Hospital | Active not recruiting | Met primary |
| Phase 4 | NCT03817788 Comparator | Apr 2019 → Apr 2020 | — | Dong Yang | Completed | No outcome recorded |
| Phase 4 | NCT03319420 Comparator | Mar 2018 → Jan 2021 | dry eye syndrome | Ocuwize LTD | Completed | No outcome recorded |
| Phase 4 | NCT03100513 Comparator | Mar 2017 → Oct 2019 | hepatic encephalopathy | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT02956057 Comparator | Nov 2016 → May 2017 | — | Tomas Bata Hospital, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT02781493 Background | Jun 2016 → Mar 2017 | — | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT02761213 Comparator | Apr 2016 → Aug 2017 | colonic disorder | Bo-In Lee | Completed | Met primary |
| Phase 4 | NCT02547571 Comparator | Mar 2016 → Sep 2018 | — | Alan Barkun | Completed | No outcome recorded |
| Phase 4 | NCT02486536 Comparator | Jul 2015 → Jun 2017 | small intestine disorder | Zhizheng Ge | Completed | No outcome recorded |
| Phase 4 | NCT02419534 Comparator | Nov 2014 → Nov 2016 | ulcer of anus and rectum | King Saud University | Unknown | No outcome recorded |
| Phase 4 | NCT02228616 Background | Oct 2014 → Sep 2016 | constipation disorder | Xian-Janssen Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02507037 Comparator | Jul 2014 → Aug 2015 | adenoma | Changhai Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02024022 Comparator | Feb 2014 → Sep 2015 | — | Clinical Hospital Colentina | Completed | No outcome recorded |
| Phase 4 | NCT01887158 Comparator | Jul 2013 → Jun 2014 | intestinal cancer | Ospedale Santa Maria delle Croci | Completed | No outcome recorded |
| Phase 4 | NCT01865916 Comparator | Apr 2013 → Dec 2015 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT04534465 Background | Feb → Mar 2013 | constipation disorder | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT03279341 Comparator | Dec 2012 → Mar 2016 | constipation disorder | University Hospital, Gasthuisberg | Completed | No outcome recorded |
| Phase 4 | NCT01649674 Comparator | Nov 2011 → Dec 2024 | — | National Cancer Institute, Naples | Unknown | No outcome recorded |
| Phase 4 | NCT01510977 Comparator | Nov 2011 → Feb 2013 | — | Asan Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01427296 Comparator | Sep 2011 → Mar 2014 | — | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01531140 Comparator | Nov 2010 → Nov 2011 | — | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT01140295 Comparator | Sep 2010 → May 2011 | — | Children's Hospital of Philadelphia | Terminated | No outcome recorded |
| Phase 4 | NCT01592734 Comparator | May 2010 → Nov 2011 | constipation disorder, intestinal impaction | Azienda Policlinico Umberto I | Completed | No outcome recorded |
| Phase 4 | NCT00889655 Comparator | May 2009 → May 2010 | — | Oregon Health and Science University | Unknown | No outcome recorded |
| Phase 4 | NCT00626054 Comparator | Mar 2009 → Dec 2011 | colorectal cancer | Rabin Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00677794 Comparator | Mar 2008 → Aug 2013 | — | Queen's University | Completed | No outcome recorded |
| — | NCT07426133 Background | Mar → Dec 2025 | — | Shaukat Khanum Memorial Cancer Hospital & Research Centre | Completed | No outcome recorded |
| — | NCT06436833 Comparator | May → Nov 2024 | — | Department of Medical Services Ministry of Public Health of Thailand | Unknown | No outcome recorded |
| — | NCT05878639 Comparator | Mar → Jul 2023 | inflammatory bowel disease | Second Affiliated Hospital of Wenzhou Medical University | Completed | No outcome recorded |
| — | NCT05379491 Comparator | Aug 2022 → Jun 2023 | — | Zhiguo Liu | Completed | No outcome recorded |
| — | NCT04794049 Comparator | May → Oct 2021 | colonic disorder | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| — | NCT06750445 Comparator | Jan 2020 → Jun 2024 | constipation disorder | Zhifeng Zhao, PhD | Completed | No outcome recorded |
| — | NCT03816774 Comparator | Jun 2019 → Sep 2022 | colonic neoplasm, colorectal cancer | Portuguese Oncology Institute, Coimbra | Completed | No outcome recorded |
| — | NCT02893748 Comparator | Mar 2019 | — | HyGIeaCare, Inc. | Withdrawn | No outcome recorded |
| — | NCT03436719 Background | Nov 2017 → Jul 2020 | rectal cancer | State Scientific Centre of Coloproctology, Russian Federation | Unknown | No outcome recorded |
| — | NCT06082622 Background | Mar 2016 → Apr 2019 | constipation disorder | Minia University | Completed | No outcome recorded |
| — | NCT02643316 Comparator | Dec 2015 → Aug 2019 | — | The Cleveland Clinic | Completed | No outcome recorded |
| — | NCT02530346 Comparator | Oct 2015 → Dec 2019 | — | Hospital Infantil de Mexico Federico Gomez | Unknown | No outcome recorded |
| — | NCT02540239 Comparator | Jan 2015 → Feb 2016 | adenoma | Changhai Hospital | Completed | Met primary |
| — | NCT02009202 Comparator | Nov 2012 → Jun 2014 | inflammatory bowel disease | Skane University Hospital | Completed | No outcome recorded |
| — | NCT01596686 Comparator | May → Dec 2012 | — | Clinical Hospital Colentina | Completed | No outcome recorded |
| — | NCT01675739 Background | Oct 2011 → Apr 2012 | — | Inje University | Completed | No outcome recorded |
| — | NCT01533090 Comparator | Apr → Nov 2010 | inflammatory bowel disease, malignant colon neoplasm, polyp of colon | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| — | NCT00558376 Comparator | Jan 2008 → Mar 2009 | — | Sheba Medical Center | Terminated | No outcome recorded |
| — | NCT01093274 Comparator | — | — | Rabin Medical Center | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2018-10-19 | Norgine | Results Norgine to present data for PLENVU® and XIFAXAN® at the United European Gastroenterology Week (UEG) norgine.com ↗
Seven PLENVU® related posters – one poster demonstrating PLENVU® higher efficacy compared to standard of care[i] |
| 2018-02-22 | Norgine | Results Positive new data show superiority of PLENVU® (1 LITRE PEG preparation) compared to MOVIPREP® (2 LITRE PEG + ASCORBATE) norgine.com ↗
Both PLENVU® PM/AM and PLENVU® AM/AM attained higher mean overall BBPS scores than MOVIPREP® PM/AM (6.7 and 6.6 versus 6.3; P=0.0001 and P=0.0058 respectively). |
| 2009-10-06 | Perrigo Company | Regulatory Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 perrigo.com ↗
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for over-the-counter (OTC) Polyethylene Glycol 3350, Powder for Solution. |
| 2006-05-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval of Polyethylene Glycol 3350 NF for Oral Solution tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for their ANDA for Polyethylene Glycol 3350 NF for Oral Solution, 17 gram/scoopful. |
All press releases naming this drug 7 releases
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 121 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | polyethylene glycol | “standard bowel preparation protocol, consisting of a 2-litre split-dose polyethylene glycol (PEG) regimen combined with a one-day low-residue diet and clear liquids the...” NCT07668778 ↗110“participants will be randomly assigned to receive either Polyethylene Glycol (Niflec Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) or Picosulfate Sodium/Citric...” NCT06994585 ↗ “At present, polyethylene glycol (PEG), owing to its good safety profile and relative lack of complications, is recommended in older patients (65 years or more), patients with...” NCT00626054 ↗ “Hospitalized adult patients were randomized to receive low volume (2 L polyethylene glycol and ascorbic acid, 2L PEG+ASC) or standard volume bowel preparation (4 L polyethylene...” PMID 41128725 ↗ Oct 2025 “Polyethyleneglycol (Muvinlax(r) or Nulytely is a non-absorbable electrolyte solution and does not induce electrolyte mucus secretion or significantly reduce fluid exchange in...” NCT06666556 ↗ “Subjects in Group B will use a regimen with 3L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy.” NCT06728839 ↗ “Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination” NCT05291325 ↗ “Patients will receive enteric polyethylene glycol at 100 ml/kg/dose during 4 hours, and up to 3 times, prior to surgery.” NCT02530346 ↗ “4 liters of polyethylene glycol plus bisacodyl 12 mg administered as rescue bowel preparation before repeat colonoscopy.” NCT07557173 ↗ “Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.” NCT01267981 ↗ “pharmacological interventions such as oral laxatives, of which poly-ethylene glycol is the first-line drug of choice.” NCT06082622 ↗ |
| Known as | BAY81-8430 | “Polyethylene glycol (MiraLAX, BAY81-8430)” NCT04534465 ↗ |
| Known as | Golytely | “Golytely (polyethylene glycol)” NCT00889655 ↗ |
| Known as | Lovol-esse | “2 sachets of Lovol-esse (Polyethylene glycol) in one liter of water” NCT01887158 ↗ |
| Known as | Macrogol 4000 | “3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets.” NCT04458129 ↗ |
| Known as | MiraLAX | “Polyethylene glycol (MiraLAX, BAY81-8430)” NCT04534465 ↗ |
| Known as | Movicol(PEG) | “Three or four sachet of Movicol(PEG) will be dissolved in 750 ml of water and will be given over 24 hrs as 3 doses orally by mouth or Nasogastric tube and will continue up to...” NCT04436601 ↗ |
| Known as | Moviprep | “Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)” NCT04281667 ↗1“mix four sachets of PEG (Moviprep) in 4 liters of water” NCT07328880 ↗ |
| Known as | Muvinlax(r) | “Polyethyleneglycol (Muvinlax(r) or Nulytely is a non-absorbable electrolyte solution and does not induce electrolyte mucus secretion or significantly reduce fluid exchange in...” NCT06666556 ↗ |
| Known as | Niflec | “PEG used in the present study was Niflec® (Meiji, Japan), which composed of macrogol 4,000 plus electrolytes” NCT04138004 ↗ |
| Known as | Niflec Powder | “Polyethylene Glycol (Niflec Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan)” NCT06994585 ↗ |
| Known as | Nulytely | “Polyethyleneglycol (Muvinlax(r) or Nulytely is a non-absorbable electrolyte solution and does not induce electrolyte mucus secretion or significantly reduce fluid exchange in...” NCT06666556 ↗ |
| Known as | PEG | “standard bowel preparation protocol, consisting of a 2-litre split-dose polyethylene glycol (PEG) regimen combined with a one-day low-residue diet and clear liquids the...” NCT07668778 ↗35“At present, polyethylene glycol (PEG), owing to its good safety profile and relative lack of complications, is recommended in older patients (65 years or more), patients with...” NCT00626054 ↗ “The objective of this study was to compare the bowel preparation efficacy of picosulfate/magnesium citrate (PMC) vs polyethylene glycol (PEG) in a one-day vs two-day split dose regimen.” PMID 30921345 ↗ Mar 2019 “Two bowel preparation regimens of Polyethylene Glycol (PEG), commonly referred to as "Golytely" will be tested for their efficacy (bowel cleansing effect) and patient tolerability.” NCT00687830 ↗ “After standard BP of split-dose polyethylene glycol (PEG) was completed, patients were randomized (1:1) to the individualized group or standard group.” PMID 37735023 ↗ Sep 2023 “Polyethylene glycol (PEG) is in a class of medications called osmotic laxatives which works by causing water to be retained with the stool.” NCT04436601 ↗ “The aim of this study was to identify the optimal dose and timing of polyethylene glycol (PEG) for small bowel preparation before VCE.” PMID 31682026 ↗ Dec 2019 “no trial has investigated the effect of gum chewing on bowel preparation for colonoscopy in addition to polyethylene glycol (PEG).” PMID 27327849 ↗ Jun 2016 “The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet” NCT03830489 ↗ “Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen” NCT03765216 ↗ “the Lct + 3 L polyethylene glycol (PEG) group (group A), the 3 L PEG group (group B), or the Lct + 2 L PEG group (group C)” PMID 40423516 ↗ May 2025 |
| Known as | PEG-EL | “reference PEG-electrolyte (PEG-EL) formulation” PMID 23152962 ↗ Nov 2012 |
| Known as | PEG-ELS | “polyethylene glycol (PEG-ELS) and bisacodyl tablets” NCT01044394 ↗ |
| Known as | Polyethylene glycol (PEG) | “Polyethylene glycol (PEG)” NCT02705378 ↗ |
| Known as | polyethylene glycol-3350 | “oral treatment consistent with rifaximin 200 mg three times a day for 7 days and polyethylene glycol-3350, 17 gr per day in water for 10 days” NCT04730245 ↗ |
| Known as | Polyethylene glycol: Fortrans | “Polyethylene glycol: Fortrans” NCT01531140 ↗ |
| Known as | polyethylene glycole | “polyethylene glycole (PEG) solution” NCT01649674 ↗ |
| Known as | polyethylenglycol | “oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed” NCT02530346 ↗ |
| Known as | Selg-esse 1000 | “2 envelopes of Selg-esse 1000 (polyethylene glycol) in 2 litres of water” NCT01887158 ↗ |
| Modality | Other / unclassified | “polyethylene glycol (PEG) assisted axonal fusion technique” NCT02359825 ↗ |
| Route | Oral | “Ingestion of 3L polyethylene Glycol” NCT00558376 ↗ |